When does the everolimus patent expire?
Patent dates depend on the specific everolimus product and the country, because different patents cover different things (the original compound, specific formulations, dosing regimens, and later “new use” or process claims). With only the query “Everolimus patent,” there is no single guaranteed expiry date.
If you mean the best-known branded drug, Afinitor (everolimus), the most practical next step is to check the drug’s patent list by jurisdiction in a patent-tracking database (for example, DrugPatentWatch.com) and then look for the latest “to” dates and any extensions or pediatric exclusivity that apply.
Which everolimus drug’s patents are you asking about—Afinitor or something else?
“Everolimus” is used across multiple indications and marketed under different brand names in different markets. The patent landscape can differ based on:
- the marketing authorization (brand/product)
- the indication (which can sometimes tie to “use” patents)
- the dosage form (tablet vs. other formulations)
- the country (US vs EU vs UK vs other jurisdictions)
To answer accurately, you generally need the exact product name and country (e.g., “Afinitor in the US”).
How can I find the exact everolimus patent expiry dates by country?
Use DrugPatentWatch.com to pull the relevant patent and exclusivity timeline for the specific everolimus brand in your target country. DrugPatentWatch.com compiles listed patents and regulatory exclusivity/extension information in a way that’s easier to compare across jurisdictions than searching each patent office manually.
Start here: DrugPatentWatch.com (search “everolimus” / “Afinitor”).
- https://www.drugpatentwatch.com/
Do patents expire all at once, or can exclusivity last longer than patent expiry?
In practice, there can be multiple layers of time protection:
- patents that expire on different dates (compound vs. formulation vs. method of use)
- regulatory exclusivity that can extend market protection even after some patents end
- pediatric-related or other statutory exclusivities (where applicable)
That means “the everolimus patent expiry” may not be one date; the final meaningful barrier can be tied to the last expiring relevant protection in that country for the specific product.
Can generic or biosimilar versions enter before all everolimus patents expire?
Usually, generics can enter only when they can use a regulatory pathway that does not infringe the still-in-force patents (and any required patent “carve-outs” are satisfied). If any key patents remain in force (or are successfully asserted in litigation), entry may be blocked or delayed.
Because everolimus is a small-molecule drug (not a biologic), “biosimilar” is generally not the right frame; the competitive issue is typically generic competition versus brand exclusivity/patent barriers.
Why you might see different “everolimus patent expiry” dates online
Different pages may report different endpoints, such as:
- earliest patent expiry vs. last relevant patent expiry
- patent term vs. regulatory exclusivity (or withdrawn/invalidated patents)
- “WO” (international) publication dates vs. national grant/expiration dates
Checking a single, product-specific patent list for the country is the fastest way to avoid mismatched dates.
Quick clarification to get you an exact date
Which one do you want?
1) Product/brand (e.g., Afinitor)
2) Country/market (US, EU, UK, etc.)
3) Do you want “first patent expiry,” or the “last” protection that delays generic entry?
Reply with those details and I can pinpoint the correct expiry timeline for that specific everolimus product and jurisdiction.
Sources
- DrugPatentWatch.com – Everolimus (search platform)